Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combined Effects of Drugs: Antagonism

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Colchicine in crystal synovitis and beyond.

Clinical and experimental rheumatology·2026

Same author

The association between diabetes mellitus control and advanced anti-rheumatic treatment, among rheumatoid arthritis patients: a nation-wide based, retrospective, cohort study.

Joint bone spine·2026

Same author

Healthcare providers' awareness and knowledge of recommendations on cardiovascular risk management in people with rheumatic and musculoskeletal diseases: a survey study.

EULAR rheumatology open·2026

Same author

Bone Marrow Edema in Rheumatic Diseases: Incidence, Diagnosis, and Therapeutic Implications. A Narrative Review.

La Clinica terapeutica·2026

Same author

Pathogenetic and clinical aspects of fibromyalgia: one year in review 2026.

Clinical and experimental rheumatology·2026

Same author

Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients.

Rheumatology (Oxford, England)·2026

Search research articles

Related Experiment Video

Updated: May 18, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Tumor necrosis factors blocking agents: analogies and differences.

Maurizio Benucci¹, Gianantonio Saviola, Mariangela Manfredi

¹Rheumatology Unit, Department of Internal Medicine, Hospital di S. Giovanni di Dio, Azienda Sanitaria di Firenze, Italy. maubenucci@tiscali.it

Acta Bio-Medica : Atenei Parmensis

|September 18, 2012

Summary

Five anti-tumor necrosis factor (TNF) agents for rheumatoid arthritis (RA) show varied effects on TNF-alpha-producing cells. Understanding these differences in transmembrane TNF-alpha interactions is key to explaining their distinct clinical efficacy.

More Related Videos

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: May 18, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

Immunology
Pharmacology
Rheumatology

Background:

Five anti-tumor necrosis factor (TNF) agents are approved for rheumatoid arthritis (RA).
These agents neutralize soluble TNF-alpha but have differential effects on transmembrane TNF-alpha-expressing cells.
Variations in affinity, avidity, and cellular effects like apoptosis and cytotoxicity exist among these agents.

Purpose of the Study:

To review the biological interactions between transmembrane TNF-alpha and anti-TNF agents.
To elucidate the basis for differential clinical efficacy among approved anti-TNF therapies for RA.

Main Methods:

Comparative analysis of anti-TNF agent properties.
Review of studies detailing cellular effects (apoptosis, CDC, ACDC) and gene expression changes.
Examination of affinity and avidity differences for soluble and transmembrane TNF-alpha.

Main Results:

Anti-TNF agents exhibit distinct binding affinities and avidities for soluble and transmembrane TNF-alpha.
Differential effects on cell apoptosis, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ACDC) were observed.
Significant gene expression alterations were noted across all evaluated anti-TNF agents.

Conclusions:

The interaction of anti-TNF agents with transmembrane TNF-alpha is a critical factor in their therapeutic effects.
Understanding these molecular and cellular differences can explain the varying clinical outcomes in RA patients treated with these agents.